MCID: KRT006
MIFTS: 51

Keratoconjunctivitis

Categories: Eye diseases, Infectious diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Keratoconjunctivitis

MalaCards integrated aliases for Keratoconjunctivitis:

Name: Keratoconjunctivitis 11 53 43 14 71 75 31

Classifications:



External Ids:

Disease Ontology 11 DOID:9368
ICD9CM 34 370.40
MeSH 43 D007637
NCIt 49 C34744
SNOMED-CT 68 155154005
ICD10 31 B30.0 H16.2
UMLS 71 C0022573

Summaries for Keratoconjunctivitis

MalaCards based summary: Keratoconjunctivitis is related to vernal keratoconjunctivitis and neurotrophic keratoconjunctivitis. An important gene associated with Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Tacrolimus and Glycerin have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and tongue, and related phenotypes are homeostasis/metabolism and neoplasm

Wikipedia: 75 Keratoconjunctivitis is inflammation ("-itis") of the cornea and... more...

Related Diseases for Keratoconjunctivitis

Diseases related to Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 796)
# Related Disease Score Top Affiliating Genes
1 vernal keratoconjunctivitis 32.4 RNASE3 IL4 IL13 CCL11
2 neurotrophic keratoconjunctivitis 32.3 NGF MUC5AC
3 keratoconjunctivitis sicca 32.1 TRIM21 TNF NGF MUC5AC IL4 IL1A
4 punctate epithelial keratoconjunctivitis 32.0 TRIM21 NGF MUC5AC MUC16
5 dry eye syndrome 31.3 TRIM21 TNF NGF MUC5AC MUC16 IL1A
6 keratoconus 30.9 TNF MMP3 MMP1 IL1A
7 corneal ulcer 30.8 TNF NGF MUC5AC MMP3 CCL11
8 vernal conjunctivitis 30.7 MUC5AC IL4 CCL11
9 chlamydia 30.6 TNF IL5 IL4 IL1A IFNG
10 dysentery 30.6 TNF IL1A ALB
11 corneal disease 30.5 TNF NGF IL1A ALB
12 endophthalmitis 30.4 TNF ICAM1 ALB
13 conjunctivochalasis 30.4 MUC5AC MMP3 MMP1
14 cellulitis 30.4 TNF RNASE3 IL5 ALB
15 chronic rhinitis 30.3 RNASE3 IL5 IL4 IL13
16 filamentary keratitis 30.2 MUC5AC MUC16
17 dacryoadenitis 30.2 TRIM21 IL4 IL13
18 graft-versus-host disease 30.1 TNF IL2 IFNG
19 anterior uveitis 30.1 TNF IL2 IFNG
20 macular retinal edema 30.1 TNF ICAM1 ALB
21 ige responsiveness, atopic 30.1 RNASE3 IL5 IL4 IL13 IFNG
22 neuritis 30.0 TNF IL4 IFNG
23 bullous pemphigoid 30.0 TNF RNASE3 IL5 IL4 CCL11
24 graves ophthalmopathy 30.0 TNF IFNG ICAM1
25 papillary conjunctivitis 30.0 RNASE3 MUC5AC IL5 IL4 IL13 CCL11
26 blepharoconjunctivitis 30.0 IL4 IL13
27 giant papillary conjunctivitis 30.0 RNASE3 MUC5AC IL5 IL4 IL13 CCL11
28 scleritis 29.9 TNF IL5 IL4 IFNG
29 laryngitis 29.9 TNF IL4 IL1A
30 blepharitis 29.9 TNF MUC5AC MUC16 IL4 IL2 IL13
31 conjunctivitis 29.9 TNF RNASE3 MUC16 IL5 IL4 IL2
32 polyarteritis nodosa 29.8 VCAM1 TNF ICAM1
33 thyroiditis 29.8 TNF IL4 IL2 IFNG
34 severe cutaneous adverse reaction 29.8 TNF MUC5AC IFNG
35 fibromyalgia 29.8 TNF NGF IL4
36 meningoencephalitis 29.8 TNF NGF ALB
37 uveitis 29.7 TNF IL4 IL2 IL1A IFNG ICAM1
38 hidradenitis 29.7 TNF IL1A IFNG
39 hidradenitis suppurativa 29.7 TNF IL1A IFNG
40 aspergillosis 29.7 TNF TLR9 IL5 IL4 IL1A IFNG
41 chronic conjunctivitis 29.7 TNF RNASE3 MUC5AC IL5 IL4 IL13
42 lymphadenitis 29.7 TNF TLR9 IFNG ICAM1
43 mastitis 29.7 MUC16 ICAM1 ALB
44 alpha-1-antitrypsin deficiency 29.7 TNF MMP3 MMP1 ALB
45 lichen planus 29.7 TNF IL4 IL2 IFNG ICAM1
46 exudative vitreoretinopathy 1 29.7 TNF ICAM1 ALB
47 hemorrhagic cystitis 29.6 TNF IL2 ALB
48 sleep apnea 29.6 VCAM1 TNF ICAM1 ALB
49 toxoplasmosis 29.6 TNF TLR9 IL5 IL4 IFNG
50 pleurisy 29.6 TNF MUC16 IFNG

Comorbidity relations with Keratoconjunctivitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Keratoconjunctivitis:



Diseases related to Keratoconjunctivitis

Symptoms & Phenotypes for Keratoconjunctivitis

MGI Mouse Phenotypes related to Keratoconjunctivitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.16 ALB ICAM1 IFNG IL13 IL1A IL2
2 neoplasm MP:0002006 9.97 ALB ICAM1 IFNG IL1A IL2 IL5
3 no phenotypic analysis MP:0003012 9.87 IFNG IL13 IL2 IL4 NGF TNF
4 immune system MP:0005387 9.86 ALB CCL11 ICAM1 IFNG IL13 IL1A
5 digestive/alimentary MP:0005381 9.85 ALB ICAM1 IFNG IL13 IL2 IL4
6 hematopoietic system MP:0005397 9.44 CCL11 ICAM1 IFNG IL13 IL1A IL2

Drugs & Therapeutics for Keratoconjunctivitis

Drugs for Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
2
Glycerin Approved, Investigational Phase 4 56-81-5 753
3
Rebamipide Approved, Investigational Phase 4 90098-04-7 5042
4
Iodine Approved, Investigational Phase 4 7553-56-2 807
5
Povidone-iodine Approved Phase 4 25655-41-8
6
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
7
Histamine Approved, Investigational Phase 4 51-45-6 774
8
Iron Approved Phase 4 7439-89-6 29936
9
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
10
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
13
Ofloxacin Approved Phase 4 82419-36-1 4583
14
Dipivefrin Approved Phase 4 52365-63-6 3105
15
Menthol Approved, Experimental Phase 4 1490-04-6, 2216-51-5, 15356-60-2 1254 16666 165675
16
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
17
Ethanol Approved Phase 4 64-17-5 702
18
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
19
Travoprost Approved Phase 4 157283-68-6 5282226
20
Azithromycin Approved Phase 4 83905-01-5 447043
21
Tetryzoline Approved Phase 4 84-22-0 5419
22
Coal tar Approved Phase 4 8007-45-2
23
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
24
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
25
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
26
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
27
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
28
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
29
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
30
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
31
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
32
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
33
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
34
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
35
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
36
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4 96919
37
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
38
Isotretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4, 4759-48-2 5538 444795 5282379
39
Cadexomer iodine Experimental Phase 4 94820-09-4
40
Spaglumic acid Experimental Phase 4 3106-85-2, 4910-46-7 188803 210320
41
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
42
protease inhibitors Phase 4
43 HIV Protease Inhibitors Phase 4
44 Retinol palmitate Phase 4
45 Guar Phase 4
46 Cathartics Phase 4
47 Carboxymethylcellulose Sodium Phase 4
48 Laxatives Phase 4
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4
50 Analgesics, Non-Narcotic Phase 4

Interventional clinical trials:

(show top 50) (show all 755)
# Name Status NCT ID Phase Drugs
1 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
2 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
3 Short-term Supplemental Effect of Preservative-free Low-dose Hyaluronic Acid-containing Salt Solution on Dry Eye Disease - A Randomized, Parallel-group, Double-blind, Controlled Trial Unknown status NCT03888183 Phase 4 salt solution without 0.15% HA;preservative-free 0.15% HA
4 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD). Unknown status NCT02992535 Phase 4
5 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
6 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
7 Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy Unknown status NCT01561040 Phase 4
8 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
9 Pre-surgical Ocular Surface Treatment With Intracanalicular Dexamethasone Insert and Effect on Intraocular Lens Measurement Accuracy - The PRECISION Study Unknown status NCT04530864 Phase 4 Dextenza 0.4Mg Ophthalmic Insert
10 A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
11 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
12 A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine Completed NCT00407043 Phase 4 Lotemax;Restasis
13 A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye Completed NCT02139033 Phase 4 Retaine™
14 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
15 Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca. Completed NCT01797822 Phase 4 Dexamethasone;Artificial tear
16 Treatment of Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: Corticosteroids Versus Cyclosporine Eyedrops: A Randomized Double-blind Study Completed NCT04376970 Phase 4 FLUCON®;Cyclosporine A eye drops 0.5%
17 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
18 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine
19 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
20 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
21 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
22 Evaluation of Intraoperative Use of Dexycu on the Signs and Symptoms of Dry Eye Completed NCT04184999 Phase 4 dexamethasone intraocular suspension, 9%;Prednisolone Acetate 1% Oph Susp
23 A Randomized, Double-Masked, Comparative Study Versus Systane Ultra UD, to Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome Completed NCT03319420 Phase 4 LO2A eye drops;Systane Ultra UD
24 Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Completed NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
25 Intracanalicular Dexamethasone Used in Conjunction With ILUX for the Treatment of Meibomian Gland Dysfunction (MGD) in Patients With Evaporative Dry Eye and Evidence of Clinically Significant Inflammation. Completed NCT04658927 Phase 4 Dexamethasone, 0.4mg;Prednisone acetate
26 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
27 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
28 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
29 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
30 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
31 An Open-Label, Single-Center Study to Evaluate Symptom Response and Tear Film Cooling Dynamics of Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
32 Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients Completed NCT00520260 Phase 4 bromfenac;ketorolac
33 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
34 Effect of Cequa™ in Subjects With Dry Eye Disease That Is Currently Inadequately Controlled While on Cyclosporine 0.05% Ophthalmic Emulsion Completed NCT04357795 Phase 4 CequaTM (Cyclosporine 0.09%) ophthalmic solution
35 Effect of Cequa Treatment on Accuracy of Pre-operative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery Completed NCT04342988 Phase 4 Cequa
36 Comparison of Autologous Serum Versus Preservative Free Artificial Tear in Patients With Dry Eye Due to Systemic Isotretinoin Therapy Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
37 Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02986750 Phase 4
38 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
39 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
40 The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study Completed NCT00809198 Phase 4
41 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
42 Randomized Self-Controlled Treatment With an Intracanalicular Dexamethasone Insert Compared to Topical Over the Counter Lubrication Therapy in Patients With Bilateral Ocular Surface Disease Completed NCT04237012 Phase 4 Dextenza 0.4Mg Intracanalicular Insert
43 A Phase IV, Multicenter, Randomized, Single-blinded(Evaluator), Active-controlled, Parallel Study for Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Moderate to Severe Dry Eye Disease Patients Completed NCT04127851 Phase 4 TJO-018 (HA 0.15%);Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add);TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%
44 Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye Completed NCT04091581 Phase 4 Systane Complete
45 Comparing the Effects of THERA°PEARL Eye Mask (Bausch & Lomb Inc., New York, USA) With the Use of Blephasteam® (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK). Completed NCT03318874 Phase 4 Hylo-comod
46 The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study: An Investigation on Lifitegrast's Speed of Onset in Improving Ocular Surface Health in Dry Eye Patients Completed NCT04669561 Phase 4 Lifitegrast 5% Ophthalmic Solution
47 The Utility of in Vivo Confocal Microscopy (IVCM) to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease (DED) Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
48 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
49 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
50 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive

Search NIH Clinical Center for Keratoconjunctivitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Lodoxamide
lodoxamide tromethamine

Cochrane evidence based reviews: keratoconjunctivitis

Genetic Tests for Keratoconjunctivitis

Anatomical Context for Keratoconjunctivitis

Organs/tissues related to Keratoconjunctivitis:

MalaCards : Eye, Salivary Gland, Tongue, Skin, Thyroid, Bone Marrow, Liver

Publications for Keratoconjunctivitis

Articles related to Keratoconjunctivitis:

(show top 50) (show all 4905)
# Title Authors PMID Year
1
Ocular complications of autoimmune polyendocrinopathy syndrome type 1. 53 62
17189144 2006
2
Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. 53 62
10682966 2000
3
Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. 53 62
10606937 2000
4
Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. 53 62
10469030 1999
5
Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. 53 62
10359913 1999
6
Tissue remodeling in adult vernal keratoconjunctivitis. 62
36336099 2022
7
Successful treatment and prevention of the recurrence of refractory vernal keratoconjunctivitis with dupilumab. 62
35907140 2022
8
Evaluation of corneal epithelial thickness mapping using anterior segment OCT in children with vernal keratoconjunctivitis. 62
36462126 2022
9
Paediatric ocular rosacea: diagnosis and management with an eyelid-warming device and topical azithromycin 1.5. 62
36319524 2022
10
Dual Delivery of Cyclosporin A and Etodolac Using Polymeric Nanocapsules in a Rabbit Eye Model: Ocular Biodistribution and Pharmacokinetic Study. 62
36355052 2022
11
Incidence of Bacterial and Nonbacterial Conjunctivitis in Patients With Atopic Dermatitis Treated With Dupilumab: A US Multidatabase Cohort Study. 62
35170520 2022
12
Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye. 62
36333219 2022
13
Treating Severe Pediatric Keratoconjunctivitis with Topical Cyclosporine A. 62
34731901 2022
14
Long-lasting otic medications may be a rare cause of neurogenic keratoconjunctivitis sicca in dogs. 62
36350754 2022
15
Evaluation of the factors that influence surgical outcome in conjunctival-limbal allograft transplantation. 62
36418907 2022
16
Ocular manifestations of rheumatoid arthritis. 62
36165413 2022
17
Changes in tear production in a dog with keratoconjunctivitis sicca for a year after inevitable nictitating membrane gland resection due to suspicion of a malignant tumour. 62
36049128 2022
18
A multicenter retrospective evaluation of the prevalence of known and presumed hereditary eye diseases in Lagotto Romagnolo dog breed within a referral population in Italy (2012-2020). 62
35976615 2022
19
Efficacy and Safety of Ophthalmic Preparations of Glucocorticoids in Patients with Epidemic Keratoconjunctivitis: A Systematic Review and Meta-analysis. 62
36414914 2022
20
Molecular Epidemiology of Adenoviral Keratoconjunctivitis in Korea. 62
35765877 2022
21
In Vitro efficacy of cyclosporine a and various antiseptics and antiviral drugs on adenovirus genotype 8, a common cause of epidemic keratoconjunctivitis. 62
36346478 2022
22
Evidence of epithelial remodelling but not epithelial-mesenchymal transition by transcriptome profiling in vernal keratoconjunctivitis. 62
35852814 2022
23
The Relationship between Clinical Findings and Viral Load in Adenoviral Keratoconjunctivitis. 62
35908877 2022
24
Sliding Flap for the Wide Upper Eyelid Margin Defect After Cancer Removal. 62
35184110 2022
25
Dysbiosis of Ocular Surface Microbiota in Patients With Refractive Allergic Conjunctival Diseases. 62
34879043 2022
26
Antiviral Drugs in Adenovirus-Induced Keratoconjunctivitis. 62
36296290 2022
27
Pre-test probability and likelihood ratios for clinical findings in canine leishmaniasis. 62
36183344 2022
28
Conjunctival granuloma in vernal keratoconjunctivitis. 62
35868891 2022
29
[Acute keratoconjunctivitis in a breeder of highly poisonous exotic corals]. 62
35089413 2022
30
A Case of Vernal Keratoconjunctivitis With Growth Hormone Deficiency. 62
36426321 2022
31
The effect of COVID-19 imposed lockdown on Italian children with Vernal Keratoconjunctivitis. 62
36117875 2022
32
Executive summary: Japanese guidelines for allergic conjunctival diseases 2021. 62
36096976 2022
33
Emerging therapies targeting eosinophil-mediated inflammation in chronic allergic conjunctivitis. 62
35970432 2022
34
Superior limbic keratoconjunctivitis following ptosis repair. 62
35123945 2022
35
Effects of meibomian gland dysfunction and aqueous deficiency on friction-related disease. 62
35219899 2022
36
Eye enucleation and exenteration in -cattle: a retrospective study of 38 cases (2013-2020). 62
36193779 2022
37
Ocular surface characteristics in pediatric vernal keratoconjunctivitis: a clinico-cytological study. 62
36122877 2022
38
Molecular Mechanisms Linking Inflammation to Autoimmunity in Sjögren's Syndrome: Identification of New Targets. 62
36362017 2022
39
Associations between ocular and extra-ocular assessment in primary Sjögren's syndrome. 62
35716880 2022
40
Study of ocular manifestations and humoral immune response in eyes of dogs with leishmaniasis. 62
36253884 2022
41
How study of naturally occurring ocular disease in animals improves ocular health globally. 62
36198052 2022
42
Venom ophthalmia (keratoconjunctivitis) caused by nuchal gland secretion of Rhabdophis tigrinus: case report. 62
36205819 2022
43
Cyclosporine A Delivery Platform for Veterinary Ophthalmology-A New Concept for Advanced Ophthalmology. 62
36291734 2022
44
Severe extra-glandular involvement and pleural effusions complicating primary Sjogren's syndrome: a case report. 62
36253840 2022
45
Clinical profile of keratitis treated within 3 months of acute COVID-19 illness at a tertiary care eye centre. 62
35362809 2022
46
Whole genome sequencing of Moraxella bovis strains from North America reveals two genotypes with different genetic determinants. 62
36271336 2022
47
First report of the whole genome of Moraxella bovoculi genotype 1 from India and comparative genomics of Moraxella bovoculi to identify genotype-specific markers. 62
36201053 2022
48
Primary Sjögren's Syndrome Presenting as Cerebral Venous Thrombosis: A Rare Case. 62
36225515 2022
49
Prevalence and characteristics of ocular diseases in Sphynx cats: A retrospective assessment (2012-2021) and comparison with non-Sphynx cats. 62
35598106 2022
50
Bilateral microsporidial keratoconjunctivitis in a clinically healthy female receiving intravitreal steroid injections: Associations and potential risk factors. 62
35865661 2022

Variations for Keratoconjunctivitis

Expression for Keratoconjunctivitis

Search GEO for disease gene expression data for Keratoconjunctivitis.

Pathways for Keratoconjunctivitis

Pathways related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 CCL11 CD46 ICAM1 IFNG IL13 IL1A
2
Show member pathways
13.67 TNF NGF MMP3 MMP1 IL5 IL4
3
Show member pathways
13.58 CCL11 ICAM1 IFNG IL13 IL1A IL2
4
Show member pathways
13.45 TNF TLR9 NGF IL5 IL4 IL2
5
Show member pathways
13.34 CCL11 IL13 IL1A IL2 IL4 IL5
6
Show member pathways
13.3 CCL11 ICAM1 IFNG IL13 IL1A IL2
7
Show member pathways
12.85 TNF TLR9 IL2 IL1A CD46
8
Show member pathways
12.73 TNF TLR9 NGF IL2 IL1A
9
Show member pathways
12.71 TNF NGF IL5 IL4 IL2 IL1A
10 12.64 VCAM1 TNF TLR9 IL4 IL2 IFNG
11
Show member pathways
12.49 CCL11 IFNG IL1A IL4 TLR9 TNF
12
Show member pathways
12.44 IL5 IL2 IL1A IL13
13
Show member pathways
12.3 TNF MUC5AC MMP3 MMP1
14
Show member pathways
12.23 IFNG IL2 IL4 TNF
15 12.22 TNF TLR9 MMP1 IFNG
16
Show member pathways
12.22 TNF IL5 IL4 IL2 IFNG
17 12.2 TNF NGF IL1A IL13
18 12.17 TNF NGF IL4 IL1A IL13 IFNG
19
Show member pathways
12.11 TLR9 IL5 IL2 IL1A IL13
20 12.08 TNF IL5 IL4 IL2 IFNG
21 12.07 TNF IL4 IL2 IL1A IFNG ICAM1
22
Show member pathways
11.98 TNF TLR9 IL2 IFNG
23 11.97 IFNG IL13 IL1A IL2 IL4 IL5
24 11.89 TNF IL5 IL4 IL2 IL13 IFNG
25
Show member pathways
11.86 TLR9 IL4 IFNG
26 11.86 MMP1 IL5 IL4 IL2 IL13 IFNG
27 11.84 TNF TLR9 IL2 IFNG
28 11.81 TNF IL4 IL2 IFNG
29 11.81 MMP1 IL5 IL4 IL2 IFNG
30
Show member pathways
11.79 TNF IL5 IL4 IL2 IFNG
31 11.77 TNF MMP1 ICAM1
32 11.76 CCL11 IL13 IL4 IL5 TNF
33 11.74 VCAM1 TNF IL1A ICAM1
34 11.73 IL4 IL2 IFNG
35 11.67 IL5 IL4 CCL11
36 11.65 VCAM1 TNF IL1A ICAM1
37
Show member pathways
11.64 TNF IL5 IL4 IL2 IL1A IL13
38 11.62 NGF IL2 IFNG
39 11.62 IL5 IL4 IL2 IL13 IFNG CCL11
40 11.59 TNF IL4 IL2 IFNG
41 11.55 TNF IL1A ICAM1
42 11.54 VCAM1 TNF IL1A
43 11.52 TNF IL1A IFNG
44 11.51 ICAM1 IFNG VCAM1
45 11.43 TNF IL5 IL4 IL13 IFNG
46
Show member pathways
11.42 TNF IL2 IFNG
47 11.42 IL5 IL4 IL2 IFNG
48
Show member pathways
11.36 VCAM1 TNF MMP3 MMP1 IL2 IL1A
49 11.34 TNF MMP3 MMP1
50 11.31 IL5 IL4 IL2 IL13 IFNG

GO Terms for Keratoconjunctivitis

Cellular components related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.13 ALB CCL11 IFNG IL13 IL1A IL2
2 extracellular space GO:0005615 9.81 ALB CCL11 ICAM1 IFNG IL13 IL1A

Biological processes related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.32 CCL11 IL13 IL1A IL5 TLR9 TNF
2 positive regulation of gene expression GO:0010628 10.27 TNF TLR9 NGF IL4 IL1A IL13
3 response to ethanol GO:0045471 10.18 VCAM1 TNF IL2 IL13
4 positive regulation of inflammatory response GO:0050729 10.17 TNF TLR9 IL2 IFNG
5 positive regulation of interleukin-6 production GO:0032755 10.16 IFNG IL1A TLR9 TNF
6 response to virus GO:0009615 10.15 CCL11 IFNG TLR9 TNF
7 positive regulation of chemokine production GO:0032722 10.1 TNF TLR9 IFNG
8 cellular response to amyloid-beta GO:1904646 10.1 VCAM1 TNF ICAM1
9 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 10.08 IL4 IL2 IL1A
10 negative regulation of endothelial cell apoptotic process GO:2000352 10.07 IL4 IL13 ICAM1
11 positive regulation of protein-containing complex assembly GO:0031334 10.03 TNF MMP3 MMP1 IFNG
12 positive regulation of cytokine production GO:0001819 10.02 TNF TLR9 IL1A IFNG
13 positive regulation of interleukin-10 production GO:0032733 10.01 CD46 IL13 IL4 TLR9
14 positive regulation of T cell proliferation GO:0042102 10 VCAM1 IL4 IL2 CD46
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.96 TNF IL4 IL2 IL13 IFNG
16 neuroinflammatory response GO:0150076 9.93 IL4 IFNG
17 positive regulation of mononuclear cell migration GO:0071677 9.92 TNF IL4
18 positive regulation of immunoglobulin production GO:0002639 9.92 IL13 IL2 IL5 TLR9
19 membrane to membrane docking GO:0022614 9.91 VCAM1 ICAM1
20 acute inflammatory response GO:0002526 9.89 IL1A TNF VCAM1
21 negative regulation of complement-dependent cytotoxicity GO:1903660 9.85 IL4 IL13
22 positive regulation of B cell proliferation GO:0030890 9.85 TLR9 IL5 IL4 IL2 IL13
23 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.84 TNF IFNG
24 positive regulation of nitrogen compound metabolic process GO:0051173 9.83 TNF IFNG
25 positive regulation of vitamin D biosynthetic process GO:0060557 9.81 TNF IFNG
26 immune response GO:0006955 9.8 CCL11 IFNG IL13 IL1A IL2 IL4
27 microglial cell activation GO:0001774 9.32 TNF TLR9 IL4 IL13 IFNG

Molecular functions related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.5 TNF IL5 IL4 IL2 IL1A IL13

Sources for Keratoconjunctivitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....